revisión2015
revisión2015

press to zoom
ComparativaRevision
ComparativaRevision

press to zoom
revisión2015
revisión2015

press to zoom
1/2
Revisamos la evidencia científica para la estandarización de prescripciones de tratamiento según el resultado de meta análisis.

Revisión 2015 (revisión en vídeo por el autor)

Los resultados de estudios aleatorizados fase III RT vs RT+HT arrojan los siguientes resultados [1]:

 

  • Mama localmente avanzado/recidivado: Complete local response in breast: RT (88/181, 48.6%) vs. RT + HT (122/198, 61.6%), Odds ratio = 2.10 (95% CI, 1.34–3.30), p = 0.001

 

  • Cérvix en tratamiento:Complete local response in cervix: RT+/-QR: RT (173/263, 65.7%) vs. RT + HT (200/251, 79.6%), Odds ratio = 2.19 (95% CI, 1.45–3.32), p < 0.001

 

  • Cabeza y cuello avanzado: Complete local response in head & neck: RT (183/364, 50.3%) vs. RT + HT (266/353, 75.3%), Odds ratio = 3.71 (95% CI, 2.55–5.38), p < 0.001

 

  • Colorrectal avanzado/recidivado: Complete local response in rectum: RT (16/205, 7.8%) vs. RT + HT (36/208, 17.3%), Odds ratio = 2.15 (95% CI, 1.10–4.20), p = 0.025

 

  • Vejiga localmente avanzado/recidivado: Complete local response in urinary bladder: RT (35/86, 40.6%) vs. RT + HT (69/118, 58.4%), (Odds ratio = 2.40 (95% CI, 1.25–4.62), p = 0.009

 

  • Esófago preoperatorio: Complete local response in esophagus: RT (24/132, 18.2%) vs. RT + HT (47/162, 29%), Odds ratio = 2.64 (95% CI, 1.34–5.20), p = 0.005

 

  • Pulmón avanzado de células no pequeñas: Complete local response in lung: RT (2/70, 2.8%) vs. RT + HT (7/59, 11.8%), Odds ratio = 2.69 (95% CI, 0.51–14.22), p = 0.243

 

  • Superficiales: Complete local response in superficial tumors: RT (57/169, 33.7%) vs. RT + HT (75/175, 42.8%), Odds ratio = 1.48 (95% CI, 0.94–2.32), p = 0.091

 

En total: Overall complete local response in all sites: RT (685/1717, 39.8%) vs. RT + HT (967/1761, 54.9%), I2 = 28.49, Odds ratio = 2.30 (95% CI, 1.95–2.72), p < 0.001

[1] Datta NR et al, Local hyperthermia combined with radiotherapy and-/or chemotherapy: Recent advances and promises for the future. Cancer Treat Rev 2015 Nov, 41(9):742-53